News – Page 12 – Alligator Bioscience

2025-01-27

Alligator Bioscience Reports Incremental Overall Survival Benefit of mitazalimab combined with mFOLFIRINOX based on Literature-based Indirect Comparison of Outcomes

Indirect Comparison shows significant improvement of OS of mitazalimab + mFOLFIRINOX, compared to known FOLFIRINOX and NALIRIFOX outcomes Th ...

2025-01-24

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-01-22

Regulatory

Sharpened focus on mitazalimab and cost-reduction program to maximize long-term value creation Announcement of rights issue of units of appr ...

2025-01-17

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-01-16

FDA feedback reinforces manufacturing strategy reducing regulatory risk of the program Feedback confirms completed and planned CMC-work as P ...

2025-01-13

Regulatory

Today, on 13 January 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follow ...

2024-12-30

Regulatory

During the month of December, the number of shares and votes in Alligator Bioscience AB has changed due to conversion of a total of 170,681 ...

2024-12-20

Regulatory

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2024-12-13

Regulatory

13 December 2024 is the last day of trading in warrants series TO 9 in Alligator Bioscience AB (“Alligator Bioscience” or the &# ...